Nuvalent (NUVL) Director Christy Oliger Sells Shares in Acquisition

What Happened
Christy J. Oliger, a director of Nuvalent (NUVL), reported disposals on July 15, 2026 related to GlaxoSmithKline’s acquisition. She sold 1,324 shares at $124.00 per share for $164,176. In addition, two dispositions to the issuer were reported for 6,091 and 6,119 units that were cancelled/converted under the merger/tender-offer terms; outstanding restricted stock units and other awards were cashed out at the $124 offer price (net of applicable withholding), producing roughly $755,284 and $758,756 respectively. Combined, these transactions represent roughly $1.68 million in cash consideration (before withholding).

Key Details

• Transaction date: 2026-07-15. Reported as: Disposition in change of control (U) and Disposition to the issuer (D).
• Prices/values shown: 1,324 shares sold @ $124.00 = $164,176. Two issuer dispositions list N/A per-share in the filing but were converted under the $124 offer price; approximate values: 6,091 × $124 ≈ $755,284 and 6,119 × $124 ≈ $758,756.
• Filing footnotes: Merger Agreement with GSK; offer price = $124.00 per share (net to seller), RSUs and options were cancelled and converted to cash per the merger terms; amounts are net of applicable withholding taxes.
• Shares owned after the transactions: not specified in the provided filing details.
• No late filing indicated in the provided data.

Context
These disposals were part of the completion of GSK’s tender offer and subsequent merger—outstanding RSUs and stock options were cancelled and converted into cash per the Merger Agreement (not a routine open-market sale signaling sentiment). The disposition code U denotes change-of-control transactions; D indicates shares/awards turned in to the issuer. Tax withholding applied to cashouts, and the filing lists some amounts as N/A while footnotes explain the cash-out mechanics.